(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.

The three most active and biggest winners today are Royalty Pharma, Vodafone, and NetEase.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 Royalty Pharma (RPRX) 44.65 7.07% 2021-11-16 07:27:55
2 Vodafone (VOD) 16.26 5.72% 2021-11-16 07:28:53
3 NetEase (NTES) 117.10 5.32% 2021-11-16 07:27:11
4 BeiGene (BGNE) 400.00 4.61% 2021-11-16 07:14:14
5 Arcturus Therapeutics (ARCT) 36.95 4% 2021-11-16 07:29:31
6 Castle Biosciences (CSTL) 54.04 3.13% 2021-11-16 04:54:23
7 Merrimack Pharmaceuticals (MACK) 4.56 2.93% 2021-11-16 04:17:43
8 Liberty Broadband (LBRDK) 173.06 2.66% 2021-11-16 04:17:28
9 Sabre Corporation (SABR) 9.46 2.6% 2021-11-16 07:27:57
10 Futu Holdings (FUTU) 62.73 2.43% 2021-11-16 07:30:28

The three most active and biggest losers today are Riot Blockchain, DouYu, and Marathon.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 Riot Blockchain (RIOT) 38.27 -9.08% 2021-11-16 07:31:33
2 DouYu (DOYU) 3.50 -7.16% 2021-11-16 07:30:15
3 Marathon (MARA) 52.36 -5.49% 2021-11-16 07:26:37
4 Arena Pharmaceuticals (ARNA) 56.51 -3.98% 2021-11-16 04:10:17
5 MercadoLibre (MELI) 1569.50 -3.9% 2021-11-16 07:26:42
6 Peloton (PTON) 45.99 -3.16% 2021-11-16 07:31:25
7 FAT Brands (FAT) 11.05 -3.07% 2021-11-16 04:59:53
8 MicroStrategy (MSTR) 770.93 -3.03% 2021-11-16 07:26:53
9 Sun Communities (SUI) 185.05 -2.88% 2021-11-16 07:23:05
10 Novavax (NVAX) 168.31 -2.4% 2021-11-16 07:27:17

Most Active Premarket Winners today

1. Royalty Pharma (RPRX) – Premarket: 7.07%

NASDAQ Composite ended the session with Royalty Pharma dropping 0.52% to $41.70 on Tuesday, following the last session’s upward trend. NASDAQ Composite fell 0.04% to $15,853.85, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for Royalty Pharma is 4323750, 100.48% above its average volume of 2156610.

Royalty Pharma’s last close was $41.92, 21.25% under its 52-week high of $53.23.

Royalty Pharma’s Sales

Royalty Pharma’s sales growth is 12.1% for the present quarter and 6.2% for the next. The company’s growth estimates for the ongoing quarter and the next is 41.7% and 171.4%, respectively.

Royalty Pharma’s Revenue

Year-on-year quarterly revenue growth grew by 8.6%, now sitting on 2.24B for the twelve trailing months.

Volatility

Royalty Pharma’s last week, last month’s, and last quarter’s current intraday variation average was 1.95%, 0.47%, and 1.58%, respectively.

Royalty Pharma’s highest amplitude of average volatility was 4.25% (last week), 2.11% (last month), and 1.58% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Royalty Pharma’s stock is considered to be oversold (<=20).

Royalty Pharma’s Stock Yearly Top and Bottom Value

Royalty Pharma’s stock is valued at $41.70 at 07:34 EST, way below its 52-week high of $53.23 and way higher than its 52-week low of $34.86.

Royalty Pharma’s Moving Average

Royalty Pharma’s value is way higher than its 50-day moving average of $37.46 and above its 200-day moving average of $39.88.

More news about Royalty Pharma.

2. Vodafone (VOD) – Premarket: 5.72%

NASDAQ Composite ended the session with Vodafone sliding 0.58% to $15.38 on Tuesday while NASDAQ Composite dropped 0.04% to $15,853.85.

Volume

Today’s last reported volume for Vodafone is 3267500, 23.73% below its average volume of 4284440.

Vodafone’s last close was $15.47, 24.02% below its 52-week high of $20.36.

News about Vodafone today

  • Vodafone idea Q2 review – fund raise expected by end-fy22: icici securities. According to today’s article on Bloomberg Quint, "Though the telecom relief package has stalled payments to be made to government, and helped Vodafone Idea meet its other obligations, it is still short of funds to incur capex in the absence of equity infusion.", "Our estimates and target price remain under review as we await clarity on Vodafone Idea’s strategy."

Vodafone’s Revenue

Year-on-year quarterly revenue growth declined by 2.8%, now sitting on 43.81B for the twelve trailing months.

Volatility

Vodafone’s last week, last month’s, and last quarter’s current intraday variation average was 0.22%, 0.05%, and 1.06%, respectively.

Vodafone’s highest amplitude of average volatility was 0.70% (last week), 0.97% (last month), and 1.06% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Vodafone’s stock is considered to be oversold (<=20).

Vodafone’s Stock Yearly Top and Bottom Value

Vodafone’s stock is valued at $15.38 at 07:34 EST, way under its 52-week high of $20.36 and above its 52-week low of $14.67.

Vodafone’s Moving Average

Vodafone’s worth is below its 50-day moving average of $15.44 and below its 200-day moving average of $17.02.

Previous days news about Vodafone

  • Vodafone CEO says telecoms sector must team up, hints at deals. According to Bloomberg Quint on Sunday, 14 November, "The chief executive officer of Vodafone Group Plc said the European telecommunications industry needs to work together more, suggesting the company could potentially co-invest in rival Virgin’s roll out of fibre and even merge with competitor Three."

More news about Vodafone.

3. NetEase (NTES) – Premarket: 5.32%

NASDAQ Composite ended the session with NetEase rising 0.03% to $111.18 on Tuesday, after three successive sessions in a row of gains. NASDAQ Composite slid 0.04% to $15,853.85, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for NetEase is 2620280, 32.33% below its average volume of 3872620.

NetEase’s last close was $111.15, 17.26% under its 52-week high of $134.33.

NetEase’s Sales

NetEase’s sales growth is 13% for the ongoing quarter and 17.5% for the next. The company’s growth estimates for the present quarter and the next is 15.9% and 188.9%, respectively.

NetEase’s Revenue

Year-on-year quarterly revenue growth grew by 12.9%, now sitting on 79.46B for the twelve trailing months.

Volatility

NetEase’s last week, last month’s, and last quarter’s current intraday variation average was 3.33%, 0.77%, and 2.41%, respectively.

NetEase’s highest amplitude of average volatility was 3.33% (last week), 2.03% (last month), and 2.41% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

NetEase’s stock is considered to be oversold (<=20).

NetEase’s Stock Yearly Top and Bottom Value

NetEase’s stock is valued at $111.18 at 07:34 EST, way below its 52-week high of $134.33 and way above its 52-week low of $77.97.

NetEase’s Moving Average

NetEase’s value is way higher than its 50-day moving average of $94.62 and way above its 200-day moving average of $100.71.

More news about NetEase.

4. BeiGene (BGNE) – Premarket: 4.61%

NASDAQ Composite ended the session with BeiGene jumping 0.97% to $382.37 on Tuesday while NASDAQ Composite slid 0.04% to $15,853.85.

Volume

Today’s last reported volume for BeiGene is 136926, 52% below its average volume of 285282.

BeiGene’s last close was $378.68, 11.22% below its 52-week high of $426.56.

BeiGene’s Sales

BeiGene’s sales growth is 188.9% for the present quarter and 161.6% for the next. The company’s growth estimates for the present quarter and the next is a negative 19.3% and a negative 0.4%, respectively.

BeiGene’s Revenue

Year-on-year quarterly revenue growth grew by 1063.8%, now sitting on 862.69M for the twelve trailing months.

Volatility

BeiGene’s last week, last month’s, and last quarter’s current intraday variation average was 0.82%, 0.28%, and 2.47%, respectively.

BeiGene’s highest amplitude of average volatility was 1.12% (last week), 1.91% (last month), and 2.47% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

BeiGene’s stock is considered to be oversold (<=20).

BeiGene’s Stock Yearly Top and Bottom Value

BeiGene’s stock is valued at $382.37 at 07:34 EST, way under its 52-week high of $426.56 and way higher than its 52-week low of $219.20.

BeiGene’s Moving Average

BeiGene’s worth is higher than its 50-day moving average of $365.71 and way above its 200-day moving average of $338.26.

More news about BeiGene.

5. Arcturus Therapeutics (ARCT) – Premarket: 4%

NASDAQ Composite ended the session with Arcturus Therapeutics dropping 5.46% to $35.53 on Tuesday while NASDAQ Composite dropped 0.04% to $15,853.85.

Volume

Today’s last reported volume for Arcturus Therapeutics is 918736, 87.24% above its average volume of 490668.

Arcturus Therapeutics’s last close was $37.58, 71.03% below its 52-week high of $129.71.

Arcturus Therapeutics’s Sales

Arcturus Therapeutics’s sales growth is 625.3% for the ongoing quarter and 1814.2% for the next. The company’s growth estimates for the ongoing quarter is a negative 72.8% and positive 6.4% for the next.

Arcturus Therapeutics’s Revenue

Year-on-year quarterly revenue growth declined by 13.8%, now sitting on 8.7M for the twelve trailing months.

Volatility

Arcturus Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.28%, a negative 1.05%, and a positive 3.66%, respectively.

Arcturus Therapeutics’s highest amplitude of average volatility was 3.88% (last week), 3.49% (last month), and 3.66% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Arcturus Therapeutics’s stock is considered to be oversold (<=20).

Arcturus Therapeutics’s Stock Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $35.53 at 07:34 EST, way under its 52-week high of $129.71 and way higher than its 52-week low of $24.87.

Arcturus Therapeutics’s Moving Average

Arcturus Therapeutics’s value is way under its 50-day moving average of $44.81 and way under its 200-day moving average of $40.32.

More news about Arcturus Therapeutics.

6. Castle Biosciences (CSTL) – Premarket: 3.13%

NASDAQ Composite ended the session with Castle Biosciences jumping 1.39% to $52.40 on Tuesday, after four successive sessions in a row of losses. NASDAQ Composite dropped 0.04% to $15,853.85, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Castle Biosciences is 252457, 49.38% above its average volume of 168996.

Castle Biosciences’s last close was $51.68, 52.01% under its 52-week high of $107.69.

Castle Biosciences’s Sales

Castle Biosciences’s sales growth is 53.2% for the present quarter and 39.2% for the next. The company’s growth estimates for the present quarter and the next is a negative 73.9% and a negative 69.6%, respectively.

Castle Biosciences’s Revenue

Year-on-year quarterly revenue growth grew by 31%, now sitting on 68.04M for the twelve trailing months.

Volatility

Castle Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.26%, a negative 1.06%, and a positive 2.97%, respectively.

Castle Biosciences’s highest amplitude of average volatility was 2.26% (last week), 3.19% (last month), and 2.97% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Castle Biosciences’s stock is considered to be overbought (>=80).

Castle Biosciences’s Stock Yearly Top and Bottom Value

Castle Biosciences’s stock is valued at $52.40 at 07:34 EST, way below its 52-week high of $107.69 and way higher than its 52-week low of $43.37.

Castle Biosciences’s Moving Average

Castle Biosciences’s value is way under its 50-day moving average of $63.83 and way below its 200-day moving average of $67.01.

More news about Castle Biosciences.

7. Merrimack Pharmaceuticals (MACK) – Premarket: 2.93%

NASDAQ Composite ended the session with Merrimack Pharmaceuticals sliding 1.56% to $4.43 on Tuesday, after two successive sessions in a row of gains. NASDAQ Composite fell 0.04% to $15,853.85, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Merrimack Pharmaceuticals is 5587, 73.02% below its average volume of 20712.

Merrimack Pharmaceuticals’s last close was $4.50, 52.38% below its 52-week high of $9.45.

Volatility

Merrimack Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.78%, a negative 0.62%, and a positive 2.72%, respectively.

Merrimack Pharmaceuticals’s highest amplitude of average volatility was 3.06% (last week), 3.02% (last month), and 2.72% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Merrimack Pharmaceuticals’s stock is considered to be oversold (<=20).

Merrimack Pharmaceuticals’s Stock Yearly Top and Bottom Value

Merrimack Pharmaceuticals’s stock is valued at $4.43 at 07:34 EST, way under its 52-week high of $9.45 and way above its 52-week low of $3.56.

Merrimack Pharmaceuticals’s Moving Average

Merrimack Pharmaceuticals’s value is below its 50-day moving average of $4.61 and way below its 200-day moving average of $5.53.

More news about Merrimack Pharmaceuticals.

8. Liberty Broadband (LBRDK) – Premarket: 2.66%

NASDAQ Composite ended the session with Liberty Broadband jumping 0.79% to $168.58 on Tuesday while NASDAQ Composite fell 0.04% to $15,853.85.

Volume

Today’s last reported volume for Liberty Broadband is 696424, 2.91% below its average volume of 717298.

Liberty Broadband’s last close was $167.26, 13.81% under its 52-week high of $194.05.

The company’s growth estimates for the present quarter and the next is 484.2% and 66.7%, respectively.

Liberty Broadband’s Revenue

Year-on-year quarterly revenue growth grew by 5789.3%, now sitting on 531.31M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Liberty Broadband’s stock is considered to be overbought (>=80).

Liberty Broadband’s Stock Yearly Top and Bottom Value

Liberty Broadband’s stock is valued at $168.58 at 07:34 EST, way below its 52-week high of $194.05 and way above its 52-week low of $142.63.

Liberty Broadband’s Moving Average

Liberty Broadband’s value is below its 50-day moving average of $171.44 and below its 200-day moving average of $172.69.

More news about Liberty Broadband.

9. Sabre Corporation (SABR) – Premarket: 2.6%

NASDAQ Composite ended the session with Sabre Corporation sliding 1.07% to $9.22 on Tuesday while NASDAQ Composite slid 0.04% to $15,853.85.

Volume

Today’s last reported volume for Sabre Corporation is 5276760, 22.37% below its average volume of 6798040.

Sabre Corporation’s last close was $9.32, 44.79% under its 52-week high of $16.88.

Sabre Corporation’s Sales

Sabre Corporation’s sales growth is 67.7% for the ongoing quarter and 66.3% for the next. The company’s growth estimates for the present quarter and the next is 35.4% and 42.9%, respectively.

Sabre Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 50.3%, now sitting on 1B for the twelve trailing months.

Volatility

Sabre Corporation’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.87%, a negative 1.46%, and a positive 2.95%, respectively.

Sabre Corporation’s highest amplitude of average volatility was 2.87% (last week), 3.28% (last month), and 2.95% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Sabre Corporation’s stock is considered to be overbought (>=80).

Sabre Corporation’s Stock Yearly Top and Bottom Value

Sabre Corporation’s stock is valued at $9.22 at 07:34 EST, way under its 52-week high of $16.88 and above its 52-week low of $8.62.

Sabre Corporation’s Moving Average

Sabre Corporation’s value is way below its 50-day moving average of $11.15 and way below its 200-day moving average of $12.04.

More news about Sabre Corporation.

10. Futu Holdings (FUTU) – Premarket: 2.43%

NASDAQ Composite ended the session with Futu Holdings rising 5.44% to $61.24 on Tuesday while NASDAQ Composite dropped 0.04% to $15,853.85.

Volume

Today’s last reported volume for Futu Holdings is 4399430, 37.63% below its average volume of 7054520.

Futu Holdings’s last close was $58.08, 71.56% below its 52-week high of $204.25.

The company’s growth estimates for the ongoing quarter and the next is 406.2% and 236%, respectively.

Futu Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 131.3%, now sitting on 5.56B for the twelve trailing months.

Volatility

Futu Holdings’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.02%, a negative 0.50%, and a positive 4.49%, respectively.

Futu Holdings’s highest amplitude of average volatility was 3.72% (last week), 4.60% (last month), and 4.49% (last quarter), respectively.

Futu Holdings’s Stock Yearly Top and Bottom Value

Futu Holdings’s stock is valued at $61.24 at 07:34 EST, way under its 52-week high of $204.25 and way above its 52-week low of $36.63.

Futu Holdings’s Moving Average

Futu Holdings’s worth is way under its 50-day moving average of $74.17 and way below its 200-day moving average of $113.31.

More news about Futu Holdings.

Most Active Premarket Losers Today

1. Riot Blockchain (RIOT) – Premarket: -9.08%

NASDAQ Composite ended the session with Riot Blockchain dropping 4.75% to $42.09 on Tuesday while NASDAQ Composite slid 0.04% to $15,853.85.

Volume

Today’s last reported volume for Riot Blockchain is 28541600, 131.29% above its average volume of 12339900.

Riot Blockchain’s last close was $44.19, 44.42% under its 52-week high of $79.50.

The company’s growth estimates for the current quarter and the next is 700% and 125%, respectively.

Riot Blockchain’s Revenue

Year-on-year quarterly revenue growth grew by 1668.7%, now sitting on 65.3M for the twelve trailing months.

Volatility

Riot Blockchain’s last week, last month’s, and last quarter’s current intraday variation average was 3.63%, 2.45%, and 4.87%, respectively.

Riot Blockchain’s highest amplitude of average volatility was 9.79% (last week), 6.09% (last month), and 4.87% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Riot Blockchain’s stock is considered to be oversold (<=20).

Riot Blockchain’s Stock Yearly Top and Bottom Value

Riot Blockchain’s stock is valued at $42.09 at 07:34 EST, way below its 52-week high of $79.50 and way higher than its 52-week low of $3.54.

Riot Blockchain’s Moving Average

Riot Blockchain’s worth is way higher than its 50-day moving average of $28.84 and way above its 200-day moving average of $31.43.

More news about Riot Blockchain.

2. DouYu (DOYU) – Premarket: -7.16%

NASDAQ Composite ended the session with DouYu dropping 4.8% to $3.77 on Tuesday while NASDAQ Composite dropped 0.04% to $15,853.85.

Volume

Today’s last reported volume for DouYu is 6084520, 77.11% above its average volume of 3435420.

DouYu’s last close was $3.96, 80.72% below its 52-week high of $20.54.

The company’s growth estimates for the present quarter is a negative 183.3% and positive 57.1% for the next.

DouYu’s Revenue

Year-on-year quarterly revenue growth declined by 6.8%, now sitting on 9.31B for the twelve trailing months.

Volatility

DouYu’s last week, last month’s, and last quarter’s current intraday variation average was 4.31%, 0.51%, and 4.26%, respectively.

DouYu’s highest amplitude of average volatility was 5.87% (last week), 3.69% (last month), and 4.26% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

DouYu’s stock is considered to be oversold (<=20).

DouYu’s Stock Yearly Top and Bottom Value

DouYu’s stock is valued at $3.77 at 07:34 EST, way below its 52-week high of $20.54 and way above its 52-week low of $2.89.

DouYu’s Moving Average

DouYu’s worth is way above its 50-day moving average of $3.39 and way below its 200-day moving average of $5.25.

More news about DouYu.

3. Marathon (MARA) – Premarket: -5.49%

NASDAQ Composite ended the session with Marathon sliding 27.03% to $55.40 on Tuesday while NASDAQ Composite fell 0.04% to $15,853.85.

Volume

Today’s last reported volume for Marathon is 34597800, 210.21% above its average volume of 11153000.

Marathon’s last close was $75.92, 9.02% below its 52-week high of $83.45.

Marathon’s Revenue

Year-on-year quarterly revenue growth grew by 10146.6%, now sitting on 41.95M for the twelve trailing months.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.31%, a positive 2.32%, and a positive 5.66%, respectively.

Marathon’s highest amplitude of average volatility was 11.26% (last week), 5.97% (last month), and 5.66% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Marathon’s stock is considered to be oversold (<=20).

Marathon’s Stock Yearly Top and Bottom Value

Marathon’s stock is valued at $55.40 at 07:34 EST, way below its 52-week high of $83.45 and way above its 52-week low of $2.18.

Marathon’s Moving Average

Marathon’s value is way above its 50-day moving average of $47.99 and way higher than its 200-day moving average of $34.80.

Previous days news about Marathon

  • Marathon health adds chief product and technology officer to accelerate innovation. According to Business Insider on Monday, 15 November, "In addition to being the only company in the country to offer a true Network solution for employers, Marathon Health backs its offering with performance guaranteesbased on patient engagement, provider experience, health outcomes and savings that are tied to revenue. ", "I’m excited to partner with this team and help Marathon Health transform the landscape for patients, employers and providers," says Chitoor."
  • (mara) alert: did you lose money on your marathon investment? contact johnson fistel regarding investigation. According to Benzinga on Monday, 15 November, "SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) — Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Marathon Digital Holdings, Inc. ("Marathon") (NASDAQ:MARA) and its officers and directors for violations of federal securities laws. "

More news about Marathon.

4. Arena Pharmaceuticals (ARNA) – Premarket: -3.98%

NASDAQ Composite ended the session with Arena Pharmaceuticals falling 1.88% to $58.85 on Tuesday while NASDAQ Composite slid 0.04% to $15,853.85.

Volume

Today’s last reported volume for Arena Pharmaceuticals is 269091, 49.33% below its average volume of 531142.

Arena Pharmaceuticals’s last close was $59.98, 29.44% under its 52-week high of $85.00.

The company’s growth estimates for the current quarter and the next is a negative 49.7% and a negative 15.7%, respectively.

Volatility

Arena Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.06%, a negative 0.23%, and a positive 1.96%, respectively.

Arena Pharmaceuticals’s highest amplitude of average volatility was 0.94% (last week), 2.08% (last month), and 1.96% (last quarter), respectively.

Arena Pharmaceuticals’s Stock Yearly Top and Bottom Value

Arena Pharmaceuticals’s stock is valued at $58.85 at 07:34 EST, way below its 52-week high of $85.00 and way above its 52-week low of $45.50.

Arena Pharmaceuticals’s Moving Average

Arena Pharmaceuticals’s worth is below its 50-day moving average of $60.47 and under its 200-day moving average of $61.23.

More news about Arena Pharmaceuticals.

5. MercadoLibre (MELI) – Premarket: -3.9%

NASDAQ Composite ended the session with MercadoLibre jumping 2.26% to $1,633.21 on Tuesday while NASDAQ Composite fell 0.04% to $15,853.85.

Volume

Today’s last reported volume for MercadoLibre is 294128, 18.69% below its average volume of 361759.

MercadoLibre’s last close was $1,597.15, 20.93% under its 52-week high of $2,020.00.

News about MercadoLibre today

  • E-commerce giant mercadolibre readies billion-dollar share sale. According to today’s article on Bloomberg Quint, "E-commerce retailer MercadoLibre Inc, Latin America’s most valuable company by market capitalization, is looking to raise funds with a follow-on share offering."

MercadoLibre’s Sales

MercadoLibre’s sales growth is 88.3% for the ongoing quarter and 50.9% for the next. The company’s growth estimates for the current quarter and the next is 346.4% and 184.3%, respectively.

MercadoLibre’s Revenue

Year-on-year quarterly revenue growth grew by 111.4%, now sitting on 4.7B for the twelve trailing months.

Volatility

MercadoLibre’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.36%, a positive 0.10%, and a positive 2.07%, respectively.

MercadoLibre’s highest amplitude of average volatility was 3.21% (last week), 2.14% (last month), and 2.07% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MercadoLibre’s stock is considered to be oversold (<=20).

MercadoLibre’s Stock Yearly Top and Bottom Value

MercadoLibre’s stock is valued at $1,633.21 at 07:34 EST, way below its 52-week high of $2,020.00 and way higher than its 52-week low of $1,262.38.

MercadoLibre’s Moving Average

MercadoLibre’s value is above its 50-day moving average of $1,598.26 and higher than its 200-day moving average of $1,595.73.

Previous days news about MercadoLibre

  • Mercadolibre, inc. announces equity offering. According to GlobeNewsWire on Monday, 15 November, "Founded in 1999, MercadoLibre is the largest online commerce ecosystem in Latin America, serving as an integrated regional platform and as a provider of the necessary digital and technology-based tools that allow companies and individuals to trade products and services in the region. "

More news about MercadoLibre.

6. Peloton (PTON) – Premarket: -3.16%

NASDAQ Composite ended the session with Peloton sliding 3.51% to $47.49 on Tuesday, following the last session’s downward trend. NASDAQ Composite dropped 0.04% to $15,853.85, following the last session’s downward trend on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Peloton is 12794500, 26.5% above its average volume of 10113600.

Peloton’s last close was $49.22, 71.23% under its 52-week high of $171.09.

The company’s growth estimates for the ongoing quarter and the next is a negative 630% and a negative 438.9%, respectively.

Peloton’s Revenue

Year-on-year quarterly revenue growth grew by 54.3%, now sitting on 4.02B for the twelve trailing months.

Volatility

Peloton’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.61%, a negative 3.32%, and a positive 3.68%, respectively.

Peloton’s highest amplitude of average volatility was 2.75% (last week), 5.58% (last month), and 3.68% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Peloton’s stock is considered to be overbought (>=80).

Peloton’s Stock Yearly Top and Bottom Value

Peloton’s stock is valued at $47.49 at 07:34 EST, under its 52-week low of $47.57.

Peloton’s Moving Average

Peloton’s worth is way under its 50-day moving average of $84.77 and way below its 200-day moving average of $102.80.

Previous days news about Peloton

  • Sundheim’s d1, viking both bet big on Peloton ahead of plunge. According to Bloomberg Quint on Monday, 15 November, "Dan Sundheim’s D1 Capital and Andreas Halvorsen’s Viking Global Investors both significantly boosted their holdings in exercise-equipment maker Peloton Interactive Inc. in the third quarter, ahead of this month’s 48% plunge.", "D1 padded its stake in New York-based Peloton by almost 75%, making it the firm’s sixth-biggest shareholder. "

More news about Peloton.

7. FAT Brands (FAT) – Premarket: -3.07%

NASDAQ Composite ended the session with FAT Brands rising 0.18% to $11.40 on Tuesday, after three consecutive sessions in a row of losses. NASDAQ Composite dropped 0.04% to $15,853.85, following the last session’s downward trend on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for FAT Brands is 51048, 25.32% above its average volume of 40731.

FAT Brands’s last close was $11.38, 28.83% below its 52-week high of $15.99.

The company’s growth estimates for the current quarter is a negative 100% and positive 92.2% for the next.

FAT Brands’s Revenue

Year-on-year quarterly revenue growth grew by 627.8%, now sitting on 51.19M for the twelve trailing months.

Volatility

FAT Brands’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.92%, a positive 1.33%, and a positive 3.29%, respectively.

FAT Brands’s highest amplitude of average volatility was 2.92% (last week), 4.24% (last month), and 3.29% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

FAT Brands’s stock is considered to be overbought (>=80).

FAT Brands’s Stock Yearly Top and Bottom Value

FAT Brands’s stock is valued at $11.40 at 07:34 EST, way below its 52-week high of $15.99 and way higher than its 52-week low of $5.48.

FAT Brands’s Moving Average

FAT Brands’s worth is way above its 50-day moving average of $9.80 and higher than its 200-day moving average of $10.83.

More news about FAT Brands.

8. MicroStrategy (MSTR) – Premarket: -3.03%

NASDAQ Composite ended the session with MicroStrategy dropping 2.06% to $795.00 on Tuesday, following the last session’s downward trend. NASDAQ Composite dropped 0.04% to $15,853.85, following the last session’s downward trend on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for MicroStrategy is 390228, 37.6% below its average volume of 625375.

MicroStrategy’s last close was $811.73, 38.27% under its 52-week high of $1,315.00.

The company’s growth estimates for the current quarter and the next is 183.8% and 282.1%, respectively.

MicroStrategy’s Revenue

Year-on-year quarterly revenue growth grew by 13.4%, now sitting on 506.98M for the twelve trailing months.

Volatility

MicroStrategy’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.93%, a positive 0.42%, and a positive 3.05%, respectively.

MicroStrategy’s highest amplitude of average volatility was 2.10% (last week), 2.51% (last month), and 3.05% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MicroStrategy’s stock is considered to be overbought (>=80).

MicroStrategy’s Stock Yearly Top and Bottom Value

MicroStrategy’s stock is valued at $795.00 at 07:34 EST, way under its 52-week high of $1,315.00 and way higher than its 52-week low of $185.64.

MicroStrategy’s Moving Average

MicroStrategy’s value is way above its 50-day moving average of $708.27 and way above its 200-day moving average of $632.90.

More news about MicroStrategy.

9. Sun Communities (SUI) – Premarket: -2.88%

NYSE Composite ended the session with Sun Communities falling 1.19% to $190.53 on Tuesday while NYSE Composite dropped 0.07% to $17,285.55.

Volume

Today’s last reported volume for Sun Communities is 685886, 25.89% above its average volume of 544807.

Sun Communities’s last close was $192.82, 8.17% below its 52-week high of $209.98.

Sun Communities’s Sales

Sun Communities’s sales growth is 112.2% for the present quarter and 44.6% for the next. The company’s growth estimates for the present quarter is 25.6% and a drop 12.5% for the next.

Sun Communities’s Revenue

Year-on-year quarterly revenue growth grew by 99.2%, now sitting on 1.81B for the twelve trailing months.

Volatility

Sun Communities’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.24%, a negative 0.07%, and a positive 1.00%, respectively.

Sun Communities’s highest amplitude of average volatility was 0.29% (last week), 0.54% (last month), and 1.00% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Sun Communities’s stock is considered to be overbought (>=80).

Sun Communities’s Stock Yearly Top and Bottom Value

Sun Communities’s stock is valued at $190.53 at 07:34 EST, below its 52-week high of $209.98 and way above its 52-week low of $137.43.

Sun Communities’s Moving Average

Sun Communities’s value is below its 50-day moving average of $193.55 and above its 200-day moving average of $185.20.

More news about Sun Communities.

10. Novavax (NVAX) – Premarket: -2.4%

NASDAQ Composite ended the session with Novavax rising 1.51% to $172.45 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ Composite dropped 0.04% to $15,853.85, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Novavax is 2511960, 49.71% below its average volume of 4995190.

Novavax’s last close was $169.89, 48.78% under its 52-week high of $331.68.

News about Novavax today

  • Hagens berman, national trial attoreys, encourages Novavax (nvax) investors with significant losses to contact firm's attorneys now, securities class action filed. According to today’s article on Benzinga, "If you invested in Novavax and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.", "Then, on Oct. 19, 2021 Politico reported, citing anonymous sources, that Novavax "faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards," the company’s "issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter," and the company could take until the end of 2022 to resolve its manufacturing issues."

The company’s growth estimates for the present quarter is a negative 21.8% and positive 213.7% for the next.

Novavax’s Revenue

Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 1.2B for the twelve trailing months.

Volatility

Novavax’s last week, last month’s, and last quarter’s current intraday variation average was 0.12%, 0.24%, and 4.69%, respectively.

Novavax’s highest amplitude of average volatility was 2.19% (last week), 5.48% (last month), and 4.69% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Novavax’s stock is considered to be oversold (<=20).

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $172.45 at 07:34 EST, way below its 52-week high of $331.68 and way higher than its 52-week low of $84.60.

Novavax’s Moving Average

Novavax’s worth is under its 50-day moving average of $174.69 and way below its 200-day moving average of $194.46.

More news about Novavax.

Stay up to date with our premarket winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here